• Nur Soyer, Rıdvan Ali, Mehmet Turgut, İbrahim Celalettin Haznedaroğlu, Fergün Yılmaz, İsmet Aydoğdu, Ali Pir, Volkan Karakuş, Gökhan Özgür, Cem Kiş, Funda Ceran, Gül İlhan, Melda Özkan, Müzeyyen Aslaner, İdris İnce, İrfan Yavaşoğlu, Füsun Gediz, Mehmet Sönmez, Birol Güvenç, Gülsüm Özet, Emin Kaya, Filiz Vural, Fahri Şahin, Mahmut Töbü, Raika Durusoy, and Güray Saydam.
• Department of Hematology, Faculty of Medicine, Ege University, İzmir, Turkey
• Turk J Med Sci. 2021 Jun 28; 51 (3): 1033-1042.

Background/AimThe aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis.Materials And MethodsFrom 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated.ResultsThe median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73).ConclusionWe found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.This work is licensed under a Creative Commons Attribution 4.0 International License.

21 keywords...

hide…